KR102129220B1 - 백신 요법 - Google Patents

백신 요법 Download PDF

Info

Publication number
KR102129220B1
KR102129220B1 KR1020197008710A KR20197008710A KR102129220B1 KR 102129220 B1 KR102129220 B1 KR 102129220B1 KR 1020197008710 A KR1020197008710 A KR 1020197008710A KR 20197008710 A KR20197008710 A KR 20197008710A KR 102129220 B1 KR102129220 B1 KR 102129220B1
Authority
KR
South Korea
Prior art keywords
memory
composition
abnormality
cognitive
down syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197008710A
Other languages
English (en)
Korean (ko)
Other versions
KR20190035948A (ko
Inventor
안드레아 페이퍼
안드레아스 무스
리메 마다니
파벨 바실리에비치 벨리첸코
윌리엄 모블리
Original Assignee
에이씨 이뮨 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이씨 이뮨 에스.에이. filed Critical 에이씨 이뮨 에스.에이.
Publication of KR20190035948A publication Critical patent/KR20190035948A/ko
Application granted granted Critical
Publication of KR102129220B1 publication Critical patent/KR102129220B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197008710A 2011-09-23 2011-09-23 백신 요법 Active KR102129220B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167021791A Division KR20160099732A (ko) 2011-09-23 2011-09-23 백신 요법

Publications (2)

Publication Number Publication Date
KR20190035948A KR20190035948A (ko) 2019-04-03
KR102129220B1 true KR102129220B1 (ko) 2020-07-02

Family

ID=47018510

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197008710A Active KR102129220B1 (ko) 2011-09-23 2011-09-23 백신 요법
KR1020137002631A Ceased KR20160005380A (ko) 2011-09-23 2011-09-23 백신 요법
KR1020167021791A Ceased KR20160099732A (ko) 2011-09-23 2011-09-23 백신 요법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137002631A Ceased KR20160005380A (ko) 2011-09-23 2011-09-23 백신 요법
KR1020167021791A Ceased KR20160099732A (ko) 2011-09-23 2011-09-23 백신 요법

Country Status (23)

Country Link
US (1) US20240270829A1 (enExample)
EP (1) EP2758071B1 (enExample)
JP (1) JP6110861B2 (enExample)
KR (3) KR102129220B1 (enExample)
CN (2) CN104039346A (enExample)
AU (1) AU2012312126B2 (enExample)
BR (1) BR112014006871A2 (enExample)
CA (1) CA2811188C (enExample)
DK (1) DK2758071T3 (enExample)
EA (1) EA032494B1 (enExample)
ES (1) ES2712951T3 (enExample)
HU (1) HUE041277T2 (enExample)
IL (1) IL231564A0 (enExample)
MX (1) MX350928B (enExample)
MY (1) MY169574A (enExample)
PH (1) PH12014500657A1 (enExample)
PL (1) PL2758071T3 (enExample)
PT (1) PT2758071T (enExample)
SG (1) SG11201400795UA (enExample)
SI (1) SI2758071T1 (enExample)
TR (1) TR201901846T4 (enExample)
WO (1) WO2013044147A1 (enExample)
ZA (1) ZA201402071B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202112329RA (en) * 2019-05-21 2021-12-30 Ac Immune Sa Anti-abeta vaccine therapy
KR20250137159A (ko) 2023-01-26 2025-09-17 에이씨 이뮨 에스에이 항-a베타 백신 요법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811401A (pt) 1997-08-28 2000-08-29 Ajay North America E Som Iodo Processos para proteger uma substância agrìcola contra pestes que são nocivas para a substância agrìcola e para a proteção de uma substãncia agrìcola, e, composição protetora para substâncias agrìcolas
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
KR101152557B1 (ko) * 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurobiolgy of Aging, Vol. 26, pp. 383-389(2005.)

Also Published As

Publication number Publication date
JP2014531455A (ja) 2014-11-27
KR20160005380A (ko) 2016-01-15
MX2014003325A (es) 2014-05-21
NZ622653A (en) 2015-12-24
HUE041277T2 (hu) 2019-05-28
KR20190035948A (ko) 2019-04-03
PT2758071T (pt) 2019-01-11
PL2758071T3 (pl) 2019-08-30
TR201901846T4 (tr) 2019-03-21
AU2012312126B2 (en) 2016-11-10
ES2712951T3 (es) 2019-05-16
AU2012312126A1 (en) 2014-03-27
EP2758071A1 (en) 2014-07-30
MX350928B (es) 2017-09-26
DK2758071T3 (en) 2019-02-18
WO2013044147A1 (en) 2013-03-28
IL231564A0 (en) 2014-04-30
CA2811188C (en) 2020-04-28
CN104039346A (zh) 2014-09-10
EA201400376A1 (ru) 2014-09-30
ZA201402071B (en) 2017-08-30
US20240270829A1 (en) 2024-08-15
EA032494B1 (ru) 2019-06-28
CA2811188A1 (en) 2013-03-23
JP6110861B2 (ja) 2017-04-05
SI2758071T1 (sl) 2019-01-31
EP2758071B1 (en) 2018-11-28
KR20160099732A (ko) 2016-08-22
MY169574A (en) 2019-04-22
BR112014006871A2 (pt) 2017-04-04
SG11201400795UA (en) 2014-10-30
PH12014500657A1 (en) 2014-05-05
CN109847058A (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
JP5810076B2 (ja) 薬学的組成物
US8603487B2 (en) Palmitoylated AB 1-15 in a liposome as a treatment for amyloid associated diseases
US20240270829A1 (en) Vaccine Therapy
US8926983B2 (en) Method for improving memory in AD patients
US7772375B2 (en) Monoclonal antibodies that recognize epitopes of amyloid-beta
US20140294849A1 (en) Compositions and uses
US20140314837A1 (en) Vaccine Therapy
JP4934433B2 (ja) 超分子コンストラクトを含む方法および組成物
HK1197732A (en) Vaccine therapy
HK1197732B (en) Vaccine therapy
NZ622653B2 (en) Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190326

Application number text: 1020167021791

Filing date: 20160809

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190425

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190503

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200616

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200625

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200625

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250522

Start annual number: 6

End annual number: 6